ORIC Stock Forecast: Oric Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.36
−4.42% on the day

The 16 Wall Street analysts covering Oric Pharmaceuticals, Inc. hold a median 12-month price target of $22 — +192.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$800.3M
Ticker Nerd rank
53/ 100
Median analyst target
$22
Analysts covering
16
Revenue$0.0
Operating income−$45.3M
Net income−$41.5M
Free cash flow−$32.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.4%
1M
−46.6%
YTD
−10.0%
1Y
−35.9%
From 52W high
−49.8%
From 52W low
0.0%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Oric Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
76
Accruals
76
Volatility
71
Momentum
64
Quality
62
Growth
45
Issuance
32
Revisions
23

Value (76): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (23): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ORIC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORIC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26ORICHigh $26Median $22Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15
Buy
1
Hold
0
Sell
$14
Low
$22
Median
$26
High

The green dot is the last close — the median target sits +192.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
19 Nov 2026HC Wainwright & Co.MaintainsBuy$27 → $20
18 Nov 2026Wells FargoMaintainsOverweight$25 → $23
17 Nov 2026BTIGReiteratesBuy$26
17 Nov 2026CitigroupMaintainsBuy$16 → $17
28 Oct 2026BTIGReiteratesBuy$26
27 Oct 2026WedbushMaintainsOutperform$17 → $14
26 Oct 2026StifelMaintainsBuy$14 → $18
14 Oct 2026JP MorganMaintainsOverweight$23 → $26
5 Oct 2026Leerink PartnersInitiatesOutperform$26
23 Sept 2026BTIGInitiatesBuy$26
10 Aug 2026HC Wainwright & Co.MaintainsBuy$25 → $27
8 June 2026HC Wainwright & Co.ReiteratesBuy$25
15 May 2026Goldman SachsUpgradeBuy—
5 May 2026CitigroupMaintainsBuy—
2 Apr 2026HC Wainwright & Co.ReiteratesBuy—
1 Apr 2026WedbushMaintainsOutperform—
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Feb 2026CitigroupMaintainsBuy—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
24 Feb 2026WedbushReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ORIC.

Market Radar

This page is one stock. Monday covers all of them.

ORIC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ORIC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Oric Pharmaceuticals, Inc. returned −35.9% against +6.9% for the S&P 500, dividends included.

ORIC vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ORICS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ORIC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.4×

Cheaper than 37% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−41.8%

Higher than 24% of US stocks

Return on assets
−26.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oric Pharmaceuticals, Inc. has a market value of $800.3M and an enterprise value of $544.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$140.4M.

  • Diluted earnings per share, trailing twelve months: −$1.35.

  • Free cash flow in the twelve months to 30 June 2026: −$112.3M.

  • Shares outstanding: 103.6M.

  • Oric Pharmaceuticals, Inc. employs 119 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ORIC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ORICOric Pharmaceuticals, Inc.$800.3M53
SNDXSyndax Pharmaceuticals, Inc.$757.9M58
VSTMVerastem, Inc.$769.1M39
ARDXArdelyx, Inc.$751.6M57
MTRIMentari Therapeutics, Inc.$776.4M24
MGTXMeiraGTx Holdings Plc$779.9M70
RIGLRigel Pharmaceuticals, Inc.$741.7M84

Take a look at ORIC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Oric Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ORIC

What is the ORIC stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Oric Pharmaceuticals, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ORIC stock a buy right now?

Of the 16 analysts covering Oric Pharmaceuticals, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oric Pharmaceuticals, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ORIC?

As at 21 Nov 2026, Oric Pharmaceuticals, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (76 of 100).

Will ORIC stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +192.1% from the last close, and Ticker Nerd's factor model ranks Oric Pharmaceuticals, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ORIC stock forecast for 2030?

No analyst covering Oric Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $26 over the next 12 months.

How has ORIC stock performed over the past year?

Oric Pharmaceuticals, Inc. returned -35.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oric Pharmaceuticals, Inc. do?

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines.

Company

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.

CEO Dr. Jacob M. Chacko M.B.A., M.D. · 119 employees · United States · https://www.oricpharma.com